---
title: "Innovative drug concept experiences a surge, CCHT rises over 8%"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/260540294.md"
description: "The innovative drug concept has seen a surge, with CCHT rising over 8%, Xinghao Pharmaceutical and WBDE rising over 5%, and Tibet Pharmaceutical, REMEGEN, Salubris, Cosunter, and INNOCARE also following suit"
datetime: "2025-10-10T02:05:50.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/260540294.md)
  - [en](https://longbridge.com/en/news/260540294.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/260540294.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/260540294.md) | [English](https://longbridge.com/en/news/260540294.md)


# Innovative drug concept experiences a surge, CCHT rises over 8%

The innovative drug concept has seen a surge, with CCHT rising over 8%, Xinghao Pharmaceutical and WBDE rising over 5%, and Tibet Pharmaceutical, REMEGEN, Salubris, Cosunter, and INNOCARE also following suit

### 相關股票

- [RemeGen (688331.CN)](https://longbridge.com/zh-HK/quote/688331.CN.md)
- [REMEGEN (09995.HK)](https://longbridge.com/zh-HK/quote/09995.HK.md)
- [Cosunter (300436.CN)](https://longbridge.com/zh-HK/quote/300436.CN.md)
- [WBDE (002082.CN)](https://longbridge.com/zh-HK/quote/002082.CN.md)
- [Salubris (002294.CN)](https://longbridge.com/zh-HK/quote/002294.CN.md)
- [InnoCare Pharma (688428.CN)](https://longbridge.com/zh-HK/quote/688428.CN.md)
- [INNOCARE (09969.HK)](https://longbridge.com/zh-HK/quote/09969.HK.md)
- [CCHT (000661.CN)](https://longbridge.com/zh-HK/quote/000661.CN.md)

## 相關資訊與研究

- [Changchun High-Tech Industry's Unit Gets Nod for GenSci141 Ointment Clinical Trial](https://longbridge.com/zh-HK/news/276832823.md)
- [Salubris Pharmaceuticals Q3 Profit Up 31%, Revenue Rises 16%](https://longbridge.com/zh-HK/news/263023190.md)
- [Salubris Gets China Clinical Trial Nod for Fatty Liver Injection; Shares Rise 4%](https://longbridge.com/zh-HK/news/271869933.md)
- [Shenzhen Salubris Pharmaceuticals Gets China Approval for Chronic Kidney Disease Tablet Clinical Trials](https://longbridge.com/zh-HK/news/268516403.md)
- [A Look At InnoCare Pharma (SEHK:9969) Valuation As Dermatology Trials For Soficitinib Progress](https://longbridge.com/zh-HK/news/276680348.md)